An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression (Q38838178)

6 September 2017

An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression (English)

1 reference

6 September 2017

1 reference

A E Rice

1

1 reference

6 September 2017

Y E Latchman

2

1 reference

6 September 2017

J P Balint

3

1 reference

6 September 2017

J H Lee

4

1 reference

6 September 2017

E S Gabitzsch

5

1 reference

6 September 2017

F R Jones

6

1 reference

6 September 2017

language of work or name

1 reference

4 September 2015

1 reference

6 September 2017

1 reference

6 September 2017

22

1 reference

6 September 2017

9

1 reference

6 September 2017

454-462

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2015.40

6 September 2017

0 references

cites work

Human papillomavirus (HPV) in head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

A population-based study of squamous cell vaginal cancer: HPV and cofactors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Development of HPV Vaccines for HPV-associated Head and Neck Squamous Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

HPV-associated head and neck cancer: a virus-related cancer epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Human papillomavirus in cervical and head-and-neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Human papillomavirus and survival of patients with oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Clinical trials of human papillomavirus vaccines and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Comprehensive control of human papillomavirus infections and related diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

21 January 2018

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Determination of subcutaneous tumor size in athymic (nude) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Role of LAG-3 in regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.40

CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.

21 January 2018

1 reference

12 December 2020

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

1 reference

12 December 2020

Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted

1 reference

12 December 2020

Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus

1 reference

12 December 2020

The predominance of human papillomavirus type 16 in vulvar neoplasia

1 reference

12 December 2020

Therapeutic HPV DNA vaccines

1 reference

12 December 2020

Identifiers

DOI

10.1038/CGT.2015.40

1 reference

6 September 2017

1 reference